Amgen Biosimilars
FDA-Approved Products - Amgen Biosimilars
Learn more about Amgen biosimilar medicines.
We have invested over $2 billion across a portfolio of 11 biosimilar medicines approved or in development, focusing primarily on oncology, hematology and ...
Our Biosimilars - Amgen Oncology
At Amgen we are committed to changing the course of cancer treatment for more than 40 years. Learn about all of the different Amgen Oncology web propoerties ...
Deep Experience - Amgen Biosimilars
At Amgen, we specialize in unlocking the potential of biology to create new ways to combat the most difficult diseases, to better serve patients.
Amgen Biosimilars: Medicine from Biologics Experts
We are end-to-end biologics experts, with an extensive experience in all phases, from development to manufacturing, aiming to deliver a reliable supply.
Amgen Biosimilars - MVASI® (bevacizumab-awwb)
We are a long-standing biotechnology leader committed to developing the biosimilar marketplace. Invested in the development of biosimilars and novel ...
The Value of Biosimilars and Amgen's Commitment
Biosimilars have the potential to lower healthcare costs and bring savings to both patients and the healthcare system.
The Amgen Support Programs You Expect - Biosimilars
Amgen has a comprehensive patient support program. Amgen provides the same support for biosimilars as for its originator biologics.
What are Biosimilars? | BioEngage from Amgen Biosimilars
Biosimilars are manufactured in living cell lines using processes that cannot be exactly replicated from one manufacturer to the next(3). Therefore, a ...
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment ...
Developing biosimilars: The process and quality standards
Amgen biosimilars are manufactured according to the same high standards used ... Amgen's biosimilar clinical development program is designed to ...
Amgen Biosimilar Expertise - PAVBLU™ (aflibercept-ayyh)
Amgen is known worldwide as a leader in research, development, and manufacturing of complex innovator and biosimilar therapies.
BIOSIMILARS EDUCATION. Amgen is committed to being a reliable resource on biosimilars for prescribers and patients. By focusing on education, ...
Leaders in Oncology and Immunology - Amgen Biosimilars
As a leader in oncology and immunology research, Amgen is committed to using innovative biotechnology to create high-quality biosimilars for patients.
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor ...
Read the latest information about Amgen Biosimilars across various news platforms throughout 2018 to present day in the Amgen news archive.
Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch
Amgen's biosimilar carries FDA approvals to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. As the FDA noted ...
Amgen Expertise in Oncology Biosimilars - RIABNI™ (rituximab-arrx)
Amgen is a leader in biologics with a growing portfolio in biosimilars. To stay up-to-date on Amgen's advances in oncology, visit AmgenOncology.com.
Amgen plans launch of Eylea biosimilar after court ruling
Amgen is getting ready to sell a copycat of Regeneron's top-selling eye drug Eylea, even as litigation continues.
Amgen Biosimilars (@AmgenBiosim) / X
Amgen Biosimilars's posts ... – allowing more people to discover Amgen information and resources on biosimilars.